73799-63-0

Basic information

• Product Name: 3-BENZYL-3-AZABICYCLO[3.1.0]HEXANE-2,4-DIONE
• Synonyms: 3-AZA-3-BENZYLBICYCLO[3.1.0]HEXANE-2,4-DIONE;3-BENZYL-3-AZABICYCLO[3.1.0]HEXANE-2,4-DIONE
• CAS NO: 73799-63-0
• Molecular Formula: C₁₂H₁₁NO₂
• Molecular Weight: 201.22
• Mol File: 73799-63-0.mol
• Article Data: 13

Chemical Properties

• Melting Point: 92-5°C
• Appearance: /
• CAS DataBase Reference: 3-BENZYL-3-AZABICYCLO[3.1.0]HEXANE-2,4-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BENZYL-3-AZABICYCLO[3.1.0]HEXANE-2,4-DIONE(73799-63-0)
• EPA Substance Registry System: 3-BENZYL-3-AZABICYCLO[3.1.0]HEXANE-2,4-DIONE(73799-63-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 73799-63-0(Hazardous Substances Data)

Usage

General Description

3-Benzyl-3-azabicyclo[3.1.0]hexane-2,4-dione, also known as cyclazocine, is a synthetic opioid analgesic that acts as a κ-opioid receptor agonist. It has been used in the past as a strong analgesic and antitussive medication, but due to its potential for abuse and dependence, it is no longer widely used for medical purposes. Cyclazocine is a schedule I controlled substance in the United States, meaning it has a high potential for abuse and no accepted medical use. It has also been investigated for its potential as a treatment for addiction to other opioids, as it can produce similar effects to morphine but with less potential for respiratory depression and physical dependence. However, its use in this context remains limited. Cyclazocine has also been studied for its potential neuroprotective and antidepressant effects, but further research is needed to fully understand its pharmacological properties and potential therapeutic uses.

Upstream product

• 5617-74-3 3-oxabicyclo[3.1.0]hexane-2,4-dione 
• 100-46-9 benzylamine 
• 5617-69-6 3-aza-bicyclo[3.1.0]hexane-2,4-dione 
• 5617-74-3 cis-1,2-cyclopropanedicarboxylic acid anhydride 
• 696-74-2 cis-1,2-cyclopropanedicarboxylic acid 
• 200620-00-4 C₁₂H₁₁N₃O₂ 
• 1631-26-1 1-benzyl-1H-pyrrole-2,5-dione 
• 710-43-0 cis-cyclopropane-1,2-dicarboxylic acid diethyl ester 

Downstream Products

• 1431773-81-7 methyl 3-(8-(6-(3-aza-bicyclo[3.1.0]hexan-3-yl)pyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)benzoate 
• 1431772-73-4 3-(8-(6-(3-aza-bicyclo[3.1.0]hexan-3-yl)pyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)benzoic acid 
• 1420294-81-0 3-benzyl-3-azabicyclo[3.1.0]hexane hydrochloride 
• 659736-81-9 3-benzyl-2-methyl-3-azabicyclo[3.1.0]hexane 
• 285-59-6 3-azabicyclo [3.1.0]hexane 
• 70110-45-1 3-benzyl-3-aza-bicyclo[3.1.0]hexane 
• 659736-80-8 3-benzyl-4-hydroxy-4-methyl-3-azabicyclo[3.1.0]hexane-2-one 

Relevant articles and documents

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential Al ion channel (TRPA1).

9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention relates to 9-aminomethyl substituted tetracycline compounds represented by formula (I), or pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as well as a method for preparing these compounds and a pharmaceutical composition comprising the same. The present invention relates also to a use of these compounds in the preparation of a medicament for the treatment and/or prophylaxis of tetracycline drug-sensitive disease. wherein, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7, R8, R9a, R9b, R10, R11, R12, R13a and R13b are each independently as defined in the description.